Clinical Trial

Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC

Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 14, 2023 (before its estimated January 9, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is conducted to evaluate the efficacy and safety of lenvatinib, sintilimab plus Y-90 selective internal radiation therapy (SIRT) for patients with unresectable intermediate-advanced hepatocellular carcinoma (HCC).
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-16
Trial Details
NCT Number NCT05992584
Lead Sponsor Second Affiliated Hospital of Guangzhou Medical University
Conditions Hepatocellular Carcinoma
Enrollment 30 participants
Start Date 2023-08-10
Primary Completion 2026-01-09 (estimated)
Study Completion 2026-08-09 (estimated)
Updated on ClinicalTrials.gov 2023-09-14